Model
Retatrutide is a next-generation peptide designed to support weight loss and metabolic health. Similar to Semaglutide and Tirzepatide, it helps regulate appetite and promote a feeling of fullness. However, Retatrutide acts on three hormone receptors—GLP-1, GIP, and glucagon receptors—making it the first “triple agonist” in its class. Early clinical studies have demonstrated promising results, suggesting that Retatrutide may provide even greater weight loss and metabolic benefits compared to therapies that target only one or two receptors.